NCT00751764已完成1 期
An Open-Label, Single-Dose Study to Evaluate the Excretion of Moxidectin Into the Breast Milk of Lactating, Non-breastfeeding Women.
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 12 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 主要终点
- Blood samples
研究概览
简要总结
The purpose of this study is to evaluate the extent of moxidectin transfer into the breast milk of lactating women and to provide the initial pharmacokinetic and safety profile of moxidectin in lactating women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: Moxidectin (Drug)
结局指标
主要结局
Blood samples
时间窗: 4 months
次要结局
- Safety based on adverse event monitoring, vital sign measurements, 12-lead ECGs and routine lab tests.(4 months)
研究者
相似试验
已完成
1 期
A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating WomenHealthy ParticipantsNCT06720714UCB Biopharma SRL15
撤回
2 期
Pediatric Pharmacokinetics And Safety Study Of MoxidectinOnchocerciasisNCT01035619Pfizer
已完成
1 期
A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding WomenHealthyNCT06453356Pfizer12
已完成
4 期
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's DiseaseColitis, UlcerativeCrohn's DiseaseNCT02559713Takeda11
已完成
1 期
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 YearsOnchocerciasisNCT03962062Medicines Development for Global Health36